Table 1.
Association Between the Expression Level of GRHL2 and Clinicopathological Data in Bladder Cancer Tissues
| Clinicopathological Data | n | Relative Expression Level of GRHL2 (Mean±SD) | P value |
|---|---|---|---|
| Gender | >0.5 | ||
| Male | 48 | 1.478±0.126 | |
| Female | 12 | 1.553±0.276 | |
| Age (years) | >0.5 | ||
| <60 | 20 | 1.534±0.215 | |
| ≥60 | 40 | 1.479±0.189 | |
| Diameter | <0.01** | ||
| <3.0 | 35 | 1.823±0.228 | |
| ≥3.0 | 25 | 1.041±0.278 | |
| Differentiation grade | <0.05* | ||
| Well and moderate | 32 | 1.589±0.169 | |
| Poor and undifferentiated | 28 | 1.392±0.178 | |
| Tumor stage | <0.01** | ||
| T1 | 21 | 1.411±0.163 | |
| T2-T4 | 39 | 1.517±0.228 | |
| Lymph node metastasis | <0.01** | ||
| N0 | 33 | 1.127±0.144 | |
| N+ | 27 | 1.561±0.239 |
Notes: *P<0.05, **P<0.01.
Abbreviations: EMT, epithelial-mesenchymal transition; UICC, Union for International Cancer Control; CCK8, the Cell Count Proliferation; FSP1, fibroblast-specific protein 1.